Cliff Asness’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.31M Buy
134,152
+77,058
+135% +$1.9M ﹤0.01% 1856
2026
Q1
$1.08M Sell
57,094
-1,204
-2% -$20.4K ﹤0.01% 2722
2025
Q4
$781K Buy
58,298
+36,702
+170% +$454K ﹤0.01% 2688
2025
Q3
$255K Buy
21,596
+1,838
+9% +$17.1K ﹤0.01% 3158
2025
Q2
$128K Buy
19,758
+7,508
+61% +$49.4K ﹤0.01% 3136
2025
Q1
$71.7K Sell
12,250
-12,887
-51% -$92.3K ﹤0.01% 3061
2024
Q4
$175K Buy
25,137
+2,364
+10% +$16.3K ﹤0.01% 2698
2024
Q3
$130K Buy
+22,773
New +$158K ﹤0.01% 2628

Other funds holding DFTX

Cliff Asness's DFTX Position: Q2 2026 in Review

Cliff Asness increased its Definium Therapeutics (DFTX) stake by 135% in Q2 2026, buying an estimated $1.9M and bringing the position to 134,152 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Cliff Asness first reported a position in DFTX in Q3 2024 and has held it in 8 quarters since. 360 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Cliff Asness held 134,152 shares of Definium Therapeutics worth $6.31M as of Q2 2026.
  • Cliff Asness bought 77,058 Definium Therapeutics shares in Q2 2026, an estimated $1.9M.
  • Definium Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1856 holding.
  • Cliff Asness first reported a position in Definium Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 360 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.